Phase II study of OK-432 intrapleural administration followed by systemic carboplatin, pemetrexed and bevasizumab for non-squamous non-small cell lung cancer with pleuritis carcinomatosa

Phase 2

Recruiting

• Conditions: non-squamous non-small cell lung cancer with pleuritis carcinomatosa

• Registration Number: JPRN-UMIN000004199
• Lead Sponsor: Kanagawa Cancaer Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-09-14
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

Not provided

Exclusion Criteria

1)Massive pericardial effusion 2)Severe complications; myocardial infarction, unstable angina, heart failure, uncontrolled hypertension, and unconrolled diabetis mellitus, uncontrolled infection. 3)Severe bone marrow suppression 4)Previous carboplatin allergy 5)Brain metastsis 6)Hemoptysis(more than 2.5ml), continuous or treatment-required bloody sputum 7)Lung fibrosis 8)Pregnancy 9)Other inappropriate cases

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
progression free survival two months after OK-432 intrapleural administration.

Secondary Outcome Measures

Name	Time	Method
response rate overall survival progression free survival adverse events